. Four of these receptors became G protein-coupled adenosine receptorsalso called P1 purinergic receptors. Eighteen other P2 purinergic receptors evolved to bind ATP and/or other purine or pyrimidine nucleotides that are released from necrotic or apoptotic cells 5 -six P2X purinergic receptor (P2XR) homotrimers, four P2XR heterotrimers and eight P2YR G protein-coupled receptors (GPCRs) (TABLE 1) . When cells become apoptotic or are stressed by shear or changes in osmotic pressure, they release ATP through cell-surface membrane channels, principally pannexin 1 (REFS 6, 7) . In addition, various mechanisms have evolved to enable the controlled release of ATP, ADP and other nucleotides from intact cells. These include the release of nucleotides in granules from nerve terminals 8 , platelets 9 and mast cells 10 .
In this Review, we develop the idea that, following tissue injury, purinergic signalling can be divided into three temporal phases (FIG. 1) . First, there is an acute phase of purinergic signalling that lasts minutes to hours, during which ATP is rapidly released into the extracellular space from damaged or stressed cells, accumulates to high levels and has chemotactic and excitatory effects on immune cells. Second, there is a subacute phase of purinergic signalling that lasts hours to days, in which there is a decrease in the extracellular ratio of ATP/ adenosine. The reduced ATP signalling and increased activation of A2A and A2B adenosine receptors (A2ARs and A2BRs, respectively) serves to limit the extent and duration of inflammation. Third, there is a chronic phase of purinergic signalling lasting days to weeks (or longer) that is associated with a low extracellular ratio of ATP/adenosine and with the initiation and progression of wound-healing processes that sometimes cause patho logi cal tissue remodelling. In some instances, in tissues that have high cell turnover such as in chronically inflamed tumours, both extracellular ATP and adenosine may be elevated for extended periods.
ATP released from stressed, apoptotic or necrotic cells promotes rapid inflammation by binding to excitatory ATP receptors; these comprise inotropic P2XR and metabotropic P2YR subtypes that amplify T cell receptor (TCR) signalling in lymphocytes and promote inflammasome activation in macrophages and dendritic cells (DCs) [11] [12] [13] . In the extracellular space, ATP is converted to ADP and AMP by enzymes belonging to three ectonucleotidase families: namely, alkaline phosphatases, ectonucleoside triphosphate diphosphohydrolases (ENTPDases) including CD39 (also known as NTPDase 1), and ectonucleotide pyrophosphatases/ phosphodiesterases (ENPPs). NAD + and ADP-ribose, which is produced from NAD + by CD38 (also known as ADPRC1), serve as additional sources of AMP owing to the enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1, also known as CD203a or PC1)
Spare receptors
Receptors that lead to an increase in the functional potency of a response to receptor occupancy by an agonist as a result of increased receptor expression.
Pannexins
A family of membranespanning proteins consisting of pannexin 1, pannexin 2 and pannexin 3. Pannexin 1 is widely expressed and oligomerizes into a hexamer to form a single membrane channel.
through equilibrative nucleoside transporters (ENTs) or concentrative nucleoside transporters (CNTs) 17, 18 , as well as through adenosine phosphorylation to AMP by intracellular adenosine kinase. Following tissue injury, there is an induction of the ectoenzymes that degrade ATP, ADP and AMP to adenosine 19 . At the same time, hypoxia and damage-associated molecular patterns (DAMPs) released from injured cells trigger the upregulation of anti-inflammatory A2ARs and A2BRs on immune cells; this upregulation of spare receptors increases the potency of adenosine to limit the extent and duration of inflammation and to promote wound-healing processes. Excluded from this discussion are the many effects of purinergic signalling in non-immune cells, which include the regu lation of physiological processes such as wakefulness, blood pressure, nerve growth and pain, as discussed elsewhere (see .
Purinergic receptors on immune cells
Overview of P2XR and P2YR signalling in immune cells. ATP, UTP and other nucleotides can be released from apoptotic cells through pannexin 1 channels that are activated by caspase-mediated cleavage of the pannexin pore-associated carboxy-terminal autoinhibitory region 23 . ATP also can be released through additional cell-membrane channels, including other pannexins, connexins, maxichannels and P2X 7 R pores 22 . As these nucleo tides are chemoattractants, they have been 7 Rs are unusual in that they have low affinity for ATP and hence are only activated in highly inflamed tissues. Moreover, P2X 7 Rs can form large pores that allow passage of molecules as large as 900 daltons, including ATP itself. Among the metabotropic P2YRs, P2Y 1 R, P2Y 2 R, P2Y 4 R and P2Y 6 R are coupled to G q proteins, and P2Y 12 R, P2Y 13 R and P2Y 14 R are coupled to G i proteins. These G q -and G i -coupled receptors produce excitatory effects in immune cells by mobilizing calcium or reducing anti-inflammatory cAMP accumulation. P2Y 11 Rs are unusual in that they are dually coupled to G q and G s proteins, interact with P2Y 1 Rs and are absent in rodents 24 . Notable among the effects of P2YR signalling are chemotaxis and activation of phagocytes in response to P2Y 2 R 25 or P2Y 14 R 26 activation. In summary, ATP and other nucleotides are rapidly released from injured tissues and function through several P2 purinergic receptors to attract and activate immune cells.
Overview of adenosine signalling in immune cells. Of the four adenosine receptor subtypes (A1R, A2AR, A2BR and A3R), the G s protein-coupled A2ARs and A2BRs are upregulated in response to activation of immune cells and respond to adenosine binding by generating cAMP, activating protein kinase A (PKA) and limiting inflammation during the subacute phase of inflammation following tissue injury. A2ARs are expressed on most immune cells, including T cells, invariant natural killer T (iNKT) cells, monocytes, macrophages, DCs, natural killer (NK) cells, platelets, mast cells, eosinophils and B cells (TABLE 1) . Consistent with their generally antiinflammatory properties, global deletion of A2ARs in mice was found to enhance the effects of stimuli that promote inflammation or tissue injury 27 . In the immune system, A2BRs are primarily expressed by macrophages and DCs and, at lower levels, by lymphocytes and platelets. A2BRs have lower affinity In response to tissue injury, there is an acute phase of ATP release from stressed or damaged cells that results in a high ratio of ATP/adenosine. ATP and other nucleotides activate P2 purinergic receptors that stimulate chemotaxis and activation of immune cells. A second subacute phase of inflammation is associated with reduced ATP release and the induction of ectonucleotidases that decrease the ATP/adenosine ratio. In addition, the induction of adenosine receptors on activated or hypoxic immune cells increases their sensitivity to adenosine. These events limit the extent and duration of the inflammatory response. A third chronic phase of inflammation following tissue injury is associated with a low ATP/adenosine ratio and persistent adenosine receptor activation on parenchymal cells and tissue-resident macrophages. The resultant activation of A2B adenosine receptors (A2BRs) produces persistent low-grade inflammation, fibrosis and angiogenesis. DC, dendritic cell; IL-6, interleukin-6; NK cell, natural killer cell; P2X 7 R, P2X 7 purinergic receptor; T H 17 cell, T helper 17 cell; T Reg cell, regulatory T cell; VEGF, vascular endothelial growth factor. for adenosine than A2ARs and are generally only weakly activated except in inflamed tissues, in which adenosine levels are elevated. The importance of A2BR signalling is increased in inflamed tissues because these receptors are strongly upregulated in response to hypoxia and hypoxia-inducible factors (HIFs) 28 . In some cells, A2BRs have been found to both couple to G s protein and the calcium-mobilizing G q protein 29 . G q protein activation contributes to A2BR-mediated wound-healing responses, such as angiogenesis 30 and fibrosis
31
, by promoting the production of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6); these medi ators are produced more by A2BR than A2AR activation. Hence, A2BR signalling contributes to the chronic phase of wound healing following tissue injury. Although acute A2BR activation is anti-inflammatory, IL-6 production in response to A2BR signalling can favour the polarization of naive T cells towards a pro-inflammatory T helper 17 (T H 17) cell pheno type 32 . This mechanism contributes to the persistent tissue remodelling and fibrosis that occurs in chronically inflamed tissues.
Purinergic regulation of thymic T cell development and of naive T cells. Immature thymocytes undergo selection in the thymus based on the signalling properties of their newly rearranged TCRs. Positive selection leads to the survival of thymocytes that express TCRs with a threshold affinity for MHC molecules, whereas negative selection causes apoptotic deletion of thymocytes that express TCRs with a high affinity for MHC or self-antigens. The rapid cell turnover and high levels of apoptotic cell death that occur in the thymic medulla result in high extra cellular concentrations of ATP and adenosine 33 . High levels of ATP enhance thymocyte apoptosis owing to excitatory P2X 7 R activation 34 . Expression of the IL-7 receptor subunit-α (IL-7Rα), which is needed for survival of thymic precursors, is reduced as a result of strong TCR activation, and this contributes to negative selection. TCR-dependent signalling and negative selection can be inhibited by activation of A2ARs that are upregulated during early thymocyte development and that inhibit the TCR signalling pathway. A2AR signalling is required for optimal progression of double-negative thymic precursors to single-positive thymocytes that have increased IL-7Rα expression 35 (FIG. 2a) . Naive T cells that survive selection in the thymus undergo TCR-dependent homeostatic proliferation in the periphery. Similarly to thymocytes, IL-7Rα expression and survival of naive T cells is increased by A2AR activation 35 . The data suggest that P2X 7 R signalling enhances, and A2AR signalling inhibits, TCR-mediated negative selection in the thymus and deletion of naive T cells in the periphery.
Purinergic regulation of effector T cells. T cells are activated through their TCRs in response to cognate peptide-MHC complexes on antigen-presenting cells and co-stimulatory molecules such as CD80 and CD86. ATP enhances, whereas adenosine suppresses, TCRmediated responses (FIG. 2b) . PKA activation also activates cAMP-responsive element-binding protein 1 (CREB), which contributes to inhibition of the major pro-inflammatory transcription factor nuclear factor-κB (NF-κB) 42 . In a similar manner to A2AR agonists, inhibitors of phosphodiesterase isozyme 4 (PDE4) -which is the principal enzyme that degrades cAMP in immune cells -also elevate intracellular cAMP levels and lead to PKA activation, attenuating TCR signalling 42 , T cell proliferation and inflammatory cytokine production. PDE4 inhibitors enhance adenosine signalling in most immune cells 43 and have recently been showed to be effective for the treatment of psoriatic arthritis 44 . In addition to its effects on CSK, PKA activation also reduces the expression of K Ca 3.1 potassium channels (also known as SK4) in human CD4 + T cells to reduce IL-2 secretion 45 and signal transducer and activator of transcription 5 (STAT5) activation 46 . Adenosineinduced suppression of IL-2 production limits T cell proliferation and responses to co-stimulatory signals because the reduction in IL-2 also reduces expression of the co-stimulatory molecules CD28 and CD2 (REF. 47 ).
In addition, T cell activation triggers the induction of A2ARs and other negative feedback signals including SH2 domain-containing inositol-5-phosphatase 1 (SHIP1) 48 and suppressor of cytokine signalling (SOCS) family proteins 49 . Adenosine has been found to inhibit human CD8 + T cell responses by reducing Ca 2+ influx, cytokine production (IL-2, interferon-γ (IFNγ) and tumour necrosis factor (TNF)), cytotoxicity and proliferation 40, 42, 50 . In summary, following tissue injury, ATP functions to augment effector T cell activation during acute inflammation by elevating Ca 2+ , whereas adenosine suppresses subacute activation of effector T cells by activating G s -coupled A2ARs. calmodulin (CAM)-dependent activation and nuclear translocation of nuclear factor of activated T cells (NFAT), which stimulates the production of IL-2, pannexin 1 channels and other NFAT targets. Autocrine ATP release helps to sustain P2 purinergic receptor signalling and NFAT activation. Extracellular adenosine and inhibitors of phosphodiesterase isozyme 4 (PDE4) elevate cAMP and activate protein kinase A (PKA), which activates C-terminal SRC kinase (CSK), a negative regulator of LCK. This attenuates the activation of transcription factors that are downstream of TCR activation, including NFAT, nuclear factor-κB (NF-κB) and AP-1. TCR activation increases A2ARs through NF-κB-dependent induction. c | In regulatory T cells, high expression of cell surface CD39 and CD73 rapidly converts locally produced pro-inflammatory ATP to anti-inflammatory adenosine. IL-6 signalling enhances the autocrine production and release of ATP. High levels of ATP or NAD + can stimulate apoptosis owing to pore formation by P2X 7 Rs. Adenosine activates A2ARs and increases the expression of CD39, CD73, programmed cell death protein 1 (PD1) and forkhead box P3 (FOXP3). CREB, cAMP-responsive element-binding protein; CTLA4, cytotoxic T lymphocyte antigen 4; DAG, dystrophinassociated glycoprotein; ERK, extracellular signal-regulated kinase; FOXO1, forkhead box O1; JAK, Janus kinase; JNK, JUN N-terminal kinase; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PLCγ1, phospholipase Cγ1; RACK, receptor for activated C-kinase; STAT5, signal transducer and activator of transcription 5; TGFβ, transforming growth factor-β. (FIG. 3) . Once activated, iNKT cells propagate an inflammatory cascade that can exacerbate tissue injury [67] [68] [69] . CD1d-restricted lipid antigens are produced by various pathogens and by damaged host tissues 70 . Upon stimulation by lipid antigens, most iNKT cells rapidly produce IFNγ, which functions to stimulate IFNγ-inducible chemokines (CXC-chemokine ligand 9 (CXCL9), CXCL10 and CXCL11) and IL-17 that are responsible for chemotaxis of other inflammatory cells, including neutrophils 71, 72 . In the mouse liver, concanavalin A induces injury that is mediated by iNKT cell activation. Deletion of CD39 was unexpectedly found to protect the liver from concanavalin A-induced hepatitis 66 . This was attributed to ATP-dependent pore formation and iNKT cell apoptosis and may occur only as a result of severe inflammation.
Purinergic regulation of T Reg cells. Mouse regulatory T (T
As is the case in conventional T cells, A2AR is induced in iNKT cells in response to NF-κB activation 73 . Stimulation of A2ARs on iNKT cells limits iNKT cell activation and decreases their production of IFNγ while simultaneously increasing their production of transforming growth factor-β (TGFβ) and IL-10 (REF. 73 ). Hence, inflammation caused by iNKT cell activation following the acute phase of tissue injury is substantially reduced by activation of A2ARs on iNKT cells 67 . Preconditioning mice with the CD1d-restricted lipid antigen α-galactosylceramide (αGalCer) was found to protect the liver from ischaemia-reperfusion injury by increasing the expression of A2ARs on iNKT cells and by enhancing their production of IL-13. Blocking A2ARs with selective antagonists reversed these protective effects 74 . Stimulation of A2ARs on iNKT cells has been found to have a protective effect in sickle cell disease, in which iNKT cells have a major role in causing tissue inflammation and injury during vaso-occlusive events 75 . The adoptive transfer of iNKT cells worsened pulmonary function in NY1DD mice deficient in recombination-activating protein 1 (RAG1): a model of sickle cell disease in mice lacking T cells. Treatment of NY1DD Rag1 -/-mice with A2AR agonists prevented adoptively transferred iNKT cells from causing pulmonary inflammation in this model 75 . Similar findings have been reported in human studies; iNKT cells collected from the blood of patients with sickle cell disease during painful vaso-occlusive crises showed elevated levels of NF-κB activation and cytokine production that could be decreased by infusion of an A2AR agonist, regadenoson 76 . In summary, an important mechanism by which adenosine inhibits tissue damage during ischaemiareperfusion injury is by signalling through A2ARs on iNKT cells. As a consequence, A2AR agonists and antibodies that deplete iNKT cells have potential utility for treating ischaemia-reperfusion injury that occurs in different clinical settings, including in myocardial infarction, tissue transplantation and sickle cell disease.
Monocytes, macrophages, DCs and neutrophils.
During the acute phase of inflammation following tissue injury, ATP and UTP released from apoptotic cells signal through P2 purinergic receptors to recruit monocytes, DCs and neutrophils 23, 77 . All monocyte and macrophage cell lines have been found to express P2XRs and P2YRs. In monocytes, the most abundant P2XR transcripts are P2X 4 R, followed by transcripts for P2X 7 R and P2X 1 R 37 . These transcripts are expressed at much higher levels in monocytes than in lymphocytes, suggesting that they may have an important role in monocyte chemo taxis and activation. In highly inflamed tissues, ATP that is released from stressed or damaged cells binds to low affinity P2X 7 Rs on macrophages, activates the inflamma some and stimulates secretion of IL-1β, which is required for optimal polarization of IFNγ-producing CD8 + T cells 78 . A2BR expression on myeloid cells increases in response to IFNγ and limits expression of IL-1β, as well as MHC class II and TNF. A2BR signalling also induces production of pro-fibrotic IL-6 and IL-8, especially under hypoxic conditions, through mitogen-activated protein kinase (MAPK) and AP-1 (REFS 79, 80) .
With regards to P2YRs in monocytes, transcripts for P2Y 13 R and P2Y 2 R are most abundant, followed by transcript for P2Y 11 R. Monocytes that enter injured tissues can polarize into pro-inflammatory (M1) macrophages or tolerogenic or pro-angiogenic (M2) macrophages (FIG. 4a) . The tolerogenic M2 pheno type is produced in response to adenosine and is characterized by low expression of pro-inflammatory mediators, such as TNF and IL-12, and high expression of tolerogenic markers, such as IL-10, arginase 1 and VEGF [81] [82] [83] [84] . Adenosine inhibits macrophage production Figure 4 | Purinergic signalling in monocytes and macrophages. a | In monocytes, ATP and UTP released from inflamed tissues are chemotactic to monocytes, activate nuclear factor-κB (NF-κB) and favour monocyte polarization into pro-inflammatory (M1) macrophages. Adenosine signalling through A2A adenosine receptors (A2ARs) and A2BRs activates nuclear receptor subfamily 4 group A (NR4A) transcription factors that inhibit NF-κB activation and favour monocyte polarization into anti-inflammatory (M2) macrophages. A2AR and A2BR signalling increase levels of cAMP and Ca
2+
, which, along with hypoxia, increases angiogenesis by induction of vascular endothelial growth factor (VEGF). Protein kinase A (PKA) and cAMP-responsive element-binding protein (CREB)-dependent activation of CCAAT/enhancer-binding protein-β (C/EBPβ) increases anti-inflammatory interleukin-10 (IL-10) production. b | In macrophages, activation of P2X 7 purinergic receptors (P2X 7 Rs) by ATP helps to activate the NLRP3 (NOD-, LRR-and pyrin domain-containing 3) inflammasome and caspase 1 to trigger the proteolytic maturation of IL-1β and other cytokines. Engulfment of apoptotic cells by macrophages stimulates the production of cytokines (CXCL1 and CXCL2) that are chemotactic to neutrophils. Chemokine production is regulated by inhibitory A2ARs and stimulatory A3Rs. DAMP, damage-associated molecular pattern; STAT1, signal transducer and activator of transcription 1; TLR, Toll-like receptor; TNF, tumour necrosis factor; TRIF, TIR domain-containing adaptor protein inducing IFNβ. of pro-inflammatory cytokines and increases antiinflammatory IL-10 in response to lipopoly saccharide or Tat (an HIV protein) 85 . A2AR activation in conjunction with antibiotics produces a significant survival benefit in mice infected with live Escherichia coli or Staphylococcus aureus because A2AR signalling suppresses the cytokine storm that occurs in response to rapid bacterial killing. In mice, both A2ARs and A2BRs contribute to adenosine regulation of peritoneal macrophages, whereas A2BR-mediated signalling predominates in RAW 264.7 cells and mouse bone marrow-derived macrophages. Inflammation increases expression of A2ARs to limit inflammatory responses. The promoter region of A2AR contains binding sites for NF-κB, STAT1 and peroxisome proliferator-activated receptor-γ (PPARγ), and activation of these transcription factors induces A2AR expression [86] [87] [88] . Human A2AR expression is also modified by microRNA-214 (miR-214), miR-15 and miR-16 (REF. 89 ).
During the subacute phase following tissue injury (FIG. 1) , apoptotic cells are engulfed by macrophages, and adenosine is produced in sufficient quantities to activate both A2ARs and A3Rs. A2AR signalling activates G s proteins and suppresses apoptotic cell-induced formation of the neutrophil migration factors CXCL1 (also known as KC) and CXCL2 (also known as MIP2) 90 ( FIG. 4b) . This is countered by activation of G i proteincoupled A3Rs. As a result, the balance in the activation of A2ARs and A3Rs determines the amount of neutrophil chemoattractants formed. As the expression of A2ARs increases and A3Rs decreases over time during phagocytosis of apoptotic cells, adenosine gradually becomes more suppressive of the pro-inflammatory signals produced as a result of macrophage engulfment of apoptotic cells 90 . In both mice and humans, adenosine inhibits DC maturation and their production of effector cytokines needed for T H 1 cell differentiation (IL-12 and TNF), and increases their production of pro-angiogenic VEGF, IL-10 and cytokines that contribute to T H 17 cell polarization (TGFβ and IL-6) 32, [91] [92] [93] . DCs are targets for immune suppression by T Reg cells that attract DCs by activating exchange protein directly activated by cAMP 1 (EPAC1)-repressor/activator protein 1 homologue (RAP1)-dependent pathways 94 . Clusters of DCs and T Reg cells degrade ATP to adenosine through CD39 and CD73, and A2AR activation stimulates secretion of inhibitory cytokines by DCs. Immature human DCs express A1Rs and A3Rs that promote their migration towards adenosine in inflamed tissues. DC maturation is associated with decreased expression of A1Rs and A3Rs, and increased expression of A2ARs [95] [96] [97] . Adenosine signalling promotes DC polarization into a tolerogenic pheno type that is characterized by the expression of arginase 1, arginase 2 and indoleamine 2,3-dioxygenase (IDO) 98 . DCs also express A2BRs that are induced by hypoxia and/or HIF-1α [99] [100] [101] [102] . Because adenosine generally has a suppressive role in DC maturation and activation, adenosine deaminase (ADA) deficiency, which causes high systemic adeno sine levels, increases tolerogenic and angiogenic DCs 98 . Interestingly, increased ADA expression can increase immunogenicity of human DCs by degrading adenosine and by promoting the formation of stable immunological synapses [103] [104] [105] . ADA on the surface of human DCs interacts with the ADA-binding protein CD26 (also known as DPP4) on the surface of T cells. When this occurs, up to threefold less antigen is needed to achieve T cell priming 105 . Adenosine-mediated differentiation of DCs into angio genic or tolerogenic phenotypes has been shown to be functionally immuno suppressive. As an example, adeno sine treatment of DCs loaded with αGalCer before adoptive cell transfer prevents ischaemia-reperfusion-induced kidney injury. Such tolerized DCs were found to increase serum levels of IL-10 and to decrease IFNγ 91 . It has been suggested that high concentrations of adenosine that are detected in aqueous pollen extracts may be responsible for T H 2 cell-promoting effects of pollen on human DCs 106 . Treatment of DCs with adenosine also promotes solid tumour growth and neovascularization 98, 107 . Bacteria also exploit immuno suppressive adenosine signalling to reduce DC and T cell activation 100 . Neutrophils function to kill pathogens but can also produce damage to the host, especially in the setting of sterile inflammation that occurs following tissue transplantation or ischaemia-reperfusion injury. As summarized in TABLE 1 and FIG. 5 , ATP, UTP, UDP and UDP-glucose released from injured tissues are chemotactic by engaging P2Y 2 R, P2Y 6 R and P2Y 14 R on neutrophils. Chemotaxis is also stimulated by A3R activation and is reduced in the presence of selective A3AR agonists that may disrupt the adenosine chemotactic gradient or by antagonists that block A3R signalling. Pharmaceutical approaches that target these receptors might be useful to control acute lung injury due to excessive neutrophil influx in sepsis 108 . In addition to direct effects of adenosine on neutrophils, A2AR activation produces indirect inhibitory effects on neutrophil chemo taxis by reducing the production of chemotactic factors such as TNF, IL-17 (REFS 109, 110) , CXCL1, CXCL2 and/or CXCL3 (REF. 111 ). Activation of A2ARs on neutrophils also causes cAMP-dependent inhibition of oxidative activity 112 and inhibits expression of α4β1 integrin (also known as VLA4) that mediates their adhesion to endothelial cells 113 . In summary, purines released from apoptotic cells have been found to have a central role in stimulating phagocyte chemotaxis and activation by enga ging P2XRs and P2YRs. Adenosine inhibits phagocyte chemotaxis and activation through both direct and indirect effects that are mediated by A2ARs and A2BRs. Targeting P2X, P2Y and adenosine receptors may be useful for redu cing excessive inflammation that can occur as a result of ischaemia-reperfusion injury, cytokine storm in sepsis and autoimmunity. A2BR blockade to reduce IL-6 production may be useful for the treatment of renal 114 , cardiac 115 , penile 116 and pulmonary 31 fibrotic diseases.
Tissue protection by adenosine
In the sections above, we have summarized some of the key ways in which purinergic signalling affects immune cell function. Below, we discuss how purinergic signalling shapes the immune responses that occur in tissues in the context of ischaemia, autoimmunity and cancer.
Adenosine signalling in the ischaemic heart. Ischaemic preconditioning (IPC) is a protective phenomenon in which a brief episode of ischaemia renders the myocardium (and other tissues) resistant to subsequent ischaemic insults. IPC consists of two phases, an acute phase (early IPC) that develops immediately but wanes within 1-2 h, and a delayed phase (late IPC) that appears after 12-24 h and lasts for several days. Adenosine has a key role in IPC, and all four adenosine receptors have been implicated. Activation of A1R is a mediator of both early and late IPC 117 . Early IPC mediated by A1R activation is blocked by glybenclamide, an inhibitor of ATP-sensitive K + channels 117 . The role of A2BR in IPC is controversial; it seems to be important for mediating late states of IPC that depend on the induction of stress-responsive genes but, at least in some animal models, is not involved in early IPC 118 . A2AR activation on bone marrow-derived cells, particularly iNKT cells, is responsible for some of the infarct-sparing and antiinflammatory effects of A2AR agonists administered at the time of reperfusion after coronary occlusion 119 . The infarct-sparing effect of A2AR activation is associated with inhib ition of CD4 + T cells (probably iNKT cells) (FIG. 3) in the reperfused heart 120 . A cardio protective effect of activating A3R in rodents may be due to mast cell stimulation with release of ATP, metabolism of ATP to adenosine and secondary activation of A2ARs on bone marrow-derived cells 121 . A2AR activation holds promise as a therapy to reduce infarct size after myocardial infarction, as A2AR agonists can be administered during stenting following angioplasty of infarcted coronary arteries and limit injury after myocardial infarction. The AMISTAD II trial was conducted to determine whether intravenous adenosine administered to patients reduced infarct sizes following acute myocardial infarction. Adenosine failed to significantly reduce total infarct size in the AMISTAD II trial, but in a subset of patients, adenosine infusion was found to significantly reduce infarct size normalized to area at risk, which is a more precise measure of myocardial injury 122 . These data suggest that adenosine or A2AR agonists administered just before stenting have the potential to reduce myocardial infarct size.
Remodelling of the heart occurs after myocardial infarction, leading to fibrosis, dysfunction and ventricular tachycardia. Adenosine, through A2BR, has been implicated in promoting these adverse outcomes. Treatment of rats with an A2BR blocker beginning 1 week after myocardial infarction resulted in improved cardiac function and decreased susceptibility to ventricular tachycardia 115 . The use of A2BR antagonists is a promising strategy for preventing adverse tissue remodelling after tissue ischaemia.
Adenosine signalling in the ischaemic kidney. Adenosine holds promise for protecting the kidneys during renal ischaemia or renal transplantation. CD73-deficient mice progressively develop renal failure that is associ ated with autoimmune inflammatory reactions that are characterized by increased production of pro-inflammatory cytokines, IgG deposition and immune cell infiltration in the kidneys. These findings suggest that adenosine can protect the kidney by preventing the development of autoimmune and inflammatory reactions 123 . All four adenosine receptors have been implicated in renal protection. Activation of A1R stimulated phosphoinositide 3-kinase (PI3K) and PKC signalling that significantly reduced necrosis and apoptosis in renal tissue after ischaemia [124] [125] [126] . In both acute and chronic forms of kidney diseases (for example, diabetic nephropathy), A2AR signalling in macrophages, dendritic cells and iNKT cells attenuates renal injury 56, 91, [127] [128] [129] [130] . Mechanistically, A2AR activation enhances IL-10 production, inhibits macrophage infiltration, suppresses the production of pro-inflammatory cytokines by T cells and myeloid cells and increases T Reg cell expression of PD1 to provide tissue protection 56, 91, 130 . Acute A2BR signalling can also contribute to tissue protection following acute kidney injury owing to ischaemia by suppressing TNF release 131 . A2BR activation on resident renal cells, but not on bone marrow-derived cells, also reduces renal inflammation 132, 133 .
Adenosine signalling in the inflamed lung. Adenosine influences alveolar function and tissue inflammation in lung diseases. During subacute lung injury, adenosine targets A2ARs on immune cells and A2BR and A3R on both haematopoietic and non-haematopoietic cells to suppress lung inflammation and reduce pulmonary oedema and tissue damage [134] [135] [136] . During ischaemia, A2AR signalling in lung-resident cells, neutrophils and CD4 + T cells strongly reduces oedema and microvascu lar permeability and suppresses the production of pro-inflammatory cytokines and chemokines, such as TNF, IL-17 and CXCL1, thereby improving pulmonary Graft-versus-host disease (GVHD). An immune-mediated reaction that occurs following transplantation of bone marrow cells that attack the recipient. 137, 138 . A2AR stimulation may be of use for preventing the development of acute chest syndrome in sickle cell disease 75 and for reducing inflammation and organ rejection following lung transplantation.
Myeloid-derived suppressor cells
Chronic pulmonary inflammatory states, such as asthma and chronic obstructive pulmonary disease produce activation of A2BR signalling that enhances eosinophilic disease severity by increasing T H 2-type cytokine production and eosinophil recruitment and degranulation 139, 140 . Stimulation of A2BRs on human mast cells stimulates secretion of IL-4 that enhances IgE synthesis by B cells to enhance allergic inflammation 141 . A2BR activation also stimulates the production of IL-6 by myeloid cells and facilitates IL-6-dependent pulmonary fibrosis 142, 143 . In summary, A2AR agonists have potential for the treatment of acute lung inflammation that occurs in response to lung transplantation or acute chest syndrome. A2BR antagonists have potential for the treatment of asthma and pulmonary fibrosis.
Transplant rejection and autoimmunity ATP signalling generally enhances rejection of transplanted tissues and autoimmune responses. ATP release is increased by the anaphylatoxin C3a that is generated as a result of transplant rejection 11 . Blockade of P2X 7 Rs was found to diminish T H 1-and T H 17-type cytokine production in response to T cell activation and to inhibit the rejection of allografts 144 . Conversely, Cd39 -/-T Reg cells that are impaired in their ability to metabolize ATP failed to promote tolerance to allo geneic skin grafts despite expressing high levels of CD25 (also known as IL-2Rα) and cytotoxic T lymphocyte antigen 4 (CTLA4) 51 . Oxidized ATP, which is a non-selective inhibitor of the ATP receptors, reduced proliferation and effector function of T cells 145 . Oxidized ATP also reduced T cell-mediated autoimmune type 1 dia betes and experimental autoimmune encephalomyelitis (EAE) in mice 145 . Hence, P2 purinergic receptor antagonists may be useful for reducing transplant rejection and for the treatment of autoimmune diseases.
A2AR signalling has been found to inhibit autoimmune responses in many disease models. In allogeneic mixed lymphocyte reactions, A2AR stimulation expanded T Reg cell populations 146 and enhanced their expression of CD39, CD73 and CTLA4 (REF. 146 ). A2AR activation on lymphoid, non-lymphoid and non-haematopoietic cells all significantly contributed to reducing autoimmune and inflammatory reactions in colitis and inflammatory bowel disease models; therefore, reducing tissue damage, weight loss and gut permeability [147] [148] [149] . The transfer of wild-type T Reg cells prevents colitis induced by pathogenic T cells, whereas T Reg cells from mice deficient in A2AR (Adora2a -/-mice) do not prevent disease 148 . Adoptive cell transfer of T Reg cells from wild-type mice, but not from Adora2a -/-mice, also protected kidneys from ischaemiareperfusion injury 56 . In a similar T cell transfer model of graft-versus-host disease (GVHD), A2AR stimulation increased mouse survival, decreased production of pro-inflammatory cytokines (IL-6, TNF and IFNγ), increased production of anti-inflammatory cytokines (TGFβ and IL-10) and increased T Reg cell numbers in the periphery 150 . In a model of experimental glomerulonephritis, which is induced with glomeru lar basement membrane-specific antibodies, and in a model of lupus, A2AR activation protected kidneys by suppressing T cell infiltration and by favouring anti-inflammatory IL-4 and IL-10 production 83, 151 . Although A2AR signalling is generally considered to be anti-inflammatory, activation of A2ARs in the choroid plexus enhances lymphocyte entry into the brain and promotes EAE 152 . In another study, A2AR activation during the T cell expansion phase of EAE enhanced T H 17 cell responses owing to activation of γδ T cells [153] [154] [155] . Consequently, the onset of EAE was slowed in Adora2a -/-mice, and A2AR blockade was protective 152, 156 . However, selective A2AR deletion from haematopoietic cells enhanced the severity of EAE 156 . These findings suggest that, contrary to the anti-inflammatory effects of A2AR activation that have been noted in peripheral tissues, A2AR agonists should be used cautiously in cases of central nervous system (CNS) inflammation. The effects of A2BR signalling on autoimmune responses also are mixed. Although acutely anti-inflammatory, A2BR signalling enhances the expression of IL-6 and T H 17-type cytokines. Hence, EAE is alleviated by A2BR deletion or blockade 157 . In general, A2AR agonists (except in the CNS) and P2 purinergic receptor antagonists are potentially useful for the treatment of autoimmune diseases. In the case of A2BR, antagonists may be useful for suppressing long-term inflammatory responses.
Purinergic signalling in cancer
In the inflamed and hypoxic environment of solid tumours, both ATP and adenosine may remain elevated for extended periods of time. As a result, ATP and adenosine signal through ATP and adenosine receptors on tumour cells and tumour-associated immune cells, including macrophages and T cells (FIG. 6) . A2AR signalling reduces the cytotoxic activity of CD8 + T cells and NK cells [158] [159] [160] while increasing the numbers of immunosuppressive and pro-angiogenic cells -that is, T Reg cells and myeloid-derived suppressor cells (MDSCs) -that facilitate tumour growth 161 . Reducing adeno sine production by deleting or blocking CD73 has been found in some cases to activate tumour-associated T cells, reduce tumour growth and invasiveness, and increase the effectiveness of antitumour vaccines 158, [162] [163] [164] . However, B16-F10 melanoma growth and metastatic spreading was found to be insensitive to CD73 deletion 165 . The expression of CD39 and CD73 on the surface of cells in the tumour microenvironment is not limited to T Reg cells. In mice, these enzymes are expressed by several types of cancer cells [166] [167] [168] [169] [170] (in fibrosarcoma, colon, triple negative breast, melanoma, brain, mastocytoma and lymphoma), by the exosomes produced by these cells, as well as by epithelial cells, endothelial venules and multipotent mesenchymal stromal cells. CD73 expression on triple negative breast cancer cells is associated with poor clinical outcomes and increased resistance to anthracycline chemotherapy 171 . Similarly to CD73 inhibition, Nature Reviews | Immunology adenosine formation also is reduced by increasing oxygen delivery to ischaemic tissues. Supplemental oxygenation was found to reduce hypoxia-induced adenosine production in lung tumours, activate NK cells and T cells and reduce lung colonization by tumours 159 . A2AR blockade in tumours. A2AR deletion or blockade was found to slow or eliminate tumour growth and activate tumour-infiltrating T cells 172 . Similar findings in several syngeneic tumour models have stimulated great interest in targeting A2ARs for cancer immunotherapy 161 . Macrophages, DCs and other myeloid cells also are targets of A2AR-mediated immunosuppression in tumours 81, 158, 159 . Selective deletion of A2ARs on myeloid cells was found to inhibit solid tumour growth and lung colonization by tumour cells and markedly reduce IL-10 production by tumour-associated DCs, macrophages and MDSCs, while indirectly increasing antigen-specific CD8 + T cell and NK cell activation 81 . Despite the generally immunosuppressive effects of adenosine, A2AR blockade or deletion enhances tumour growth in some instances. For example, selective deletion of A2ARs from T cells markedly increased the growth of melanomas 173 . Although A2AR deletion acutely increases TCR signal strength and T cell activation, it also causes T cell exhaustion and suppresses the expression of IL-7R that is needed for T cell survival 173 (FIG. 2a) . Exhausted cells collected from tumours have impaired IFNγ production upon restimulation (C. C. and J. L., unpublished observations). T cells lacking A2ARs resemble T cells with high-avidity TCRs for the melanoma-expressed antigen transient receptor protein 2 (TRP2, also known as TRPC2), in that they only transiently inhibit melanoma growth before becoming exhausted 174 . By contrast, T cells with low-avidity TCRs do not become exhausted 174, 175 . Despite their exhausted state, adoptively transferred A2AR-deficient T cells are more effective than wildtype cells at producing a transient decrease in tumour growth. This suggests that A2AR deletion increases acute cyto toxi city, but this initial beneficial effect can be compromised by long-term T cell apoptosis and exhaustion. Therefore, A2AR blockade to stimulate high TCR signal intensity has the potential to produce beneficial therapeutic outcomes but may require careful dose optimization to control for activation-induced exhaustion and cell death. Optimal therapy may depend on engineering T cells to maintain their cytotoxicity and ability to survive during strong activation.
A2BRs in tumours.
Adenosine binding to A2BRs found on most tumour cells enhances their metastatic capacity 176 . Hence, blockade of tumour A2BRs can blunt metastases. A2BR signalling also contributes to immunosuppression in tumours. In a model of bladder cancer, inhibition of tumour growth by the non-selective adenosine receptor antagonist theophylline was mediated by A2BR blockade but not by A2AR blockade 107 . P2 purinergic receptors in tumours. Solid tumours have been found to contain high levels of ATP that engages P2 purinergic receptors on most immune cells, including P2X 7 Rs on macrophages and DCs that drive secretion of IL-1β, which is required for polarization of IFNγ-producing CD8 + T cells 78 . In P2X 7 R-deficient mice, tumour growth and metastatic spreading are accelerated, intratumoural IL-1β and VEGF release are drastically Figure 6 | Purinergic signalling in the tumour microenvironment. The solid tumour microenvironment is persistently inflamed and hypoxic and has high levels of ATP and adenosine. Most tumour cell express high levels of P2X 7 purinergic receptors (P2X 7 Rs), which stimulate cell proliferation, and of A2B adenosine receptors (A2BRs) that stimulate cell dispersal and metastasis. Myeloid lineage cells such as macrophages and dendritic cells are influenced by ATP binding to P2X 7 Rs to adopt a pro-inflammatory (M1) phenotype. Myeloid cells are influenced by adenosine binding to A2ARs and A2BRs to adopt an anti-inflammatory (M2) phenotype that inhibits immune killing of tumours. A2BR signalling also enhances tumour angiogenesis and fibrosis. Cytotoxic CD8 + T cell proliferation and killing ability in response to T cell receptor (TCR) activation is enhanced by P2X 1 R, P2X 4 R and P2Y 12 R signalling and inhibited by A2AR signalling. CAM, calmodulin; CSK, C-terminal SRC kinase; IL-6, interleukin-6; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; VEGF, vascular endothelial growth factor.
reduced, and inflammatory cell infiltration is abrogated. DCs from P2X 7 R-deficient mice are unresponsive to stimulation with tumour cells, and chemotaxis of P2X 7 R-deficient cells is impaired 177 . However, blockade of P2X 7 Rs on tumour cells inhibits their growth 178 . Hence, P2X 7 R activation has opposing effects to directly promote tumour growth and to enhance immune killing of tumour cells. Non-small cell lung cancers harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) are treated with ALK inhibitors, including crizotinib 179 . The expression by tumour cells of G q protein-coupled P2YRs (P2Y 1 R, P2Y 2 R and P2Y 6 R) confers resistance to ALK inhibitors, in part through a PKC-dependent mechanism 180 . These findings suggest that certain P2YR inhibitors may overcome resistance to ALK-dependent non-small cell lung cancers. However, it is also possible that such compounds will reduce rejection of immunogenic tumours by reducing the activity of immune cells.
Perspective
In this Review, we have discussed the prominent role that purines have in shaping the evolution of immune cell responses to injury, infection, autoimmunity and cancer. ATP and other nucleotides are rapidly released into the extracellular space in response to tissue injury and are generally chemotactic and activating to immune cells. Extracellular adenosine levels rise more slowly and act on upregulated A2ARs and A2BRs on immune cells to limit the extent and duration of inflammation. Drugs that target purinergic receptors have great potential as thera peutic agents to treat inflammation, autoimmunity or cancer. At present, only a few drugs that target purinergic receptors have been approved, but many more are in clinical development. P2X 7 R antagonists are being evaluated in preclinical models of autoimmune diseases 144, 145 and tissue transplantation 11 . Clopidogrel and other P2Y 12 R antagonists that are clinically used to block platelet aggregation may have additional antiinflammatory uses by blocking P2Y 12 Rs on leukocytes. A2BR blockers seem to have acute anti-inflammatory effects but are potentially useful for the long-term treatment of fibrotic diseases and heart failure.
Adenosine has been found to have an important role in limiting ischaemia-reperfusion injury by suppressing the activation of iNKT cells. A2AR agonists inhibit the activation of iNKT cell as well as other immune cells and have potential for treating ischaemia-reperfusion injury, such as that seen in myocardial infarction and tissue transplantation. A2AR agonists also have promise for the treatment of inflammatory flares in auto immune diseases. Similarly to A2AR agonists, therapeutic antibodies that selectively deplete iNKT cells may be useful to prevent tissue inflammation in response to vasoocclusive episodes or organ transplantation. A2AR agonists also are potentially useful for the treatment of chronic inflammatory diseases. For long-term therapy, it may be necessary to learn how to effectively apply intermittent A2AR agonist treatment to avoid desensitization while maintaining therapeutic efficacy.
Growing evidence indicates that A2AR and A2BR signalling in tumours contributes to the highly immunosuppressive tumour microenvironment. Several pharmaceutical companies are evaluating blockers of CD73 or A2ARs as exciting new cancer immunotherapeutic agents. This Review touched on three interesting recent developments regarding this approach. First, it is evident that the deletion or blockade of A2ARs on T cells activates these cells. However, activation-induced T cell exhaustion or death has been observed in some instances and underscores the point that adenosine receptor blockade and possibly other modes of T cell activation have the potential to kill T cells and consequently suppress the long-term immune response. This will be an important concept to consider as combinations of approaches to strongly activate tumour-associated T cells are investigated. Second, emerging evidence suggests a surprisingly important role for antigen-presenting cells as targets of adenosine receptor blockade in cancer. Myeloid selective deletion of A2ARs has been found in some mouse cancer models to be more effective at reducing tumour growth than global or lymphoid-selective A2AR deletion. It seems that the indirect activation of T cells through blockade of A2AR signalling in antigen-presenting cells may be more effective in stimulating antitumour immune responses that the direct activation of T cells. Third, and related to the second point, is the somewhat surprising observation that A2BR blockade is very effective at slowing tumour growth. Given the fact that there is much higher expression of A2BRs by myeloid cells than by lymphoid cells, this is consistent with the idea that antigen-presenting cells are underappreciated cellu lar targets of adenosine receptor blockade for cancer immunotherapy. One other point about the targeting of A2ARs versus A2BRs for immunotherapy relates to their relative affinities for adenosine. Although the functional potency of adenosine varies among different cells owing to variable numbers of spare receptors, in general adenosine activates A2AR responses at 10-100 times lower concentrations than are necessary to activate A2BR responses. As adenosine levels are high in solid tumours, lower levels of antagonist should be required to competitively inhibit adenosine binding to A2BRs than to A2ARs without the need to use excessively high concentrations that may produce adverse systemic side effects. As most studies of adenosine receptor blockers for cancer immunotherapy have focused on A2AR selective compounds, it will be of interest to further investigate selective A2BR blockers or compounds that block both A2ARs and A2BRs. 
